GLUT6-facilitated noncanonical glucose metabolic rewiring enables resistance to targeted cancer therapy
Huimin Lei, Ruixue Xia, Yabin Tang, Jun Lu, Chan Xiang, Yujing Li, Hongyu Liu, Peichen Zou, Ayinazhaer Aihemaiti, Wei Zhang, Ying Shen, Baohui Han, Yuchen Han, Hua Zhong, Hongzhuan Chen, Liang Zhu · 2026
Read GLUT6-facilitated noncanonical glucose metabolic rewiring enables resistance to targeted cancer therapy by Huimin Lei, Ruixue Xia, Yabin Tang, Jun Lu, Chan Xiang, Yujing Li, Hongyu Liu, Peichen Zou, Ayinazhaer Aihemaiti, Wei Zhang, Ying Shen, Baohui Han, Yuchen Han, Hua Zhong, Hongzhuan Chen, Liang Zhu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13365234.txt.
Description
Huimin Lei and a large team of co-authors expose a sugar detour that shields lung cancer from targeted drugs, in a paper dated twenty twenty-six. The transporter GLUT6 pulls glucose in and diverts it toward a toxic side product. That product switches on a defense program that blunts drug action.
A therapy-stress factor named MAZ turns GLUT6 up in the first place. Blocking GLUT6 stopped resistance to EGFR and KRAS drugs in their tests. The same chain tracked patient response and relapse in clinic data. Since GLUT6 barely serves normal body balance, the authors flag it as a clean drug target.
Catalog record
| CREATOR | Huimin Lei, Ruixue Xia, Yabin Tang, Jun Lu, Chan Xiang, Yujing Li, Hongyu Liu, Peichen Zou, Ayinazhaer Aihemaiti, Wei Zhang, Ying Shen, Baohui Han, Yuchen Han, Hua Zhong, Hongzhuan Chen, Liang Zhu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 60 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |